Lifecore Biomedical Agrees Major Commercial Site-Transfer Deal
The Minnesota injectables CDMO has signed a technical transfer and manufacturing agreement for a currently marketed, high-viscosity injectable, marking its seventh late‑stage commercial program and 11th pipeline addition in 2026.
A new commercial site‑transfer agreement has been secured by Injectables CDMO, Lifecore Biomedical, with an unnamed global pharmaceutical company to manufacture an already‑marketed injectable drug product (1). As part of the deal, Lifecore will perform technical transfer activities, including process performance qualification (PPQ) batches, to enable commercial‑scale production of the therapy. The program is expected to begin generating commercial revenues for Lifecore in 2028, once regulatory and manufacturing milestones are completed.
“This product’s unique formulation and manufacturing complexity align directly with Lifecore’s strong technical expertise in high-viscosity, complex products," said Paul Josephs, Chief Executive Officer of Lifecore, in a company press release (1). “Closing this opportunity reflects the solution-driven organization we’re building — one positioned to deliver durable, sustained growth. We’re proud to support this important therapy by applying our differentiated expertise to a technically complex manufacturing process.”
Lifecore positions itself as a fully integrated injectables CDMO with differentiated capabilities in the development and fill/finish of sterile products in syringes, vials, and cartridges, including complex formulations. It is also a leading manufacturer of injectable‑grade hyaluronic acid and says it brings more than 40 years of experience supporting global and emerging biopharma and biotech customers across multiple therapeutic areas.
For the unnamed pharma company, Lifecore’s established U.S.‑based sterile manufacturing network undoubtedly offers a route to diversify supply and potentially scale output of a therapy the company describes as having “meaningful patient impact”. For Lifecore, the program is flagged as potentially one of its largest contracts, underlining the financial significance of its push into late‑stage, lower‑risk work.
The latest deal extends the company’s customer base to include another large, global pharmaceutical partner, complementing a series of earlier 2026 site‑transfer and expansion agreements with U.S. and international sponsors. The agreement adds to a series of deals for Lifecore in 2026, taking its late‑stage commercial pipeline to 13 programs with revenue potential by the end of 2028.
With 11 new pipeline additions in 2026 and a growing roster of site‑transfer deals, the company is betting that its focus on technically demanding sterile products will sustain growth through the end of the decade.
Reference
Lifecore Biomedical. Lifecore Biomedical Signs Agreement for Commercial Site Transfer Supporting Global Pharmaceutical Company. Press Release, Sept. 2, 2026.